Last reviewed · How we verify
Peripheral Mobilization of Hematopoietic Stem Cells
Approved treatments
- Mozobil · Sanofi
Mozobil works by binding to the C-C chemokine receptor type 2, which helps to mobilize hematopoietic stem cells from the bone marrow into the bloodstream. - Mozobil · University of Washington
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Peripheral Mobilization of Hematopoietic Stem Cells patent landscape — cliff calendar, originator estates, attackable patents
- Peripheral Mobilization of Hematopoietic Stem Cells treatment landscape brief
- Peripheral Mobilization of Hematopoietic Stem Cells treatment updates RSS
Frequently asked questions about Peripheral Mobilization of Hematopoietic Stem Cells
What drugs treat Peripheral Mobilization of Hematopoietic Stem Cells?
Tracked treatments include Mozobil.
What is the treatment for Peripheral Mobilization of Hematopoietic Stem Cells?
Standard treatment for Peripheral Mobilization of Hematopoietic Stem Cells includes Mozobil. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Peripheral Mobilization of Hematopoietic Stem Cells patent cliff · Peripheral Mobilization of Hematopoietic Stem Cells CI report
- Treatment: Mozobil · Sanofi
- Treatment: Mozobil · University of Washington
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing